SciCombinator

Discover the most talked about and latest scientific content & concepts.

Recent developments in nanocarrier-aided mucosal vaccination

Nanomedicine (London, England) | 26 Apr 2017

O Kammona, V Bourganis, T Karamanidou and C Kiparissides
Abstract
To date, most of the licensed vaccines for mucosal delivery are based on live-attenuated viruses which carry the risk of regaining their pathogenicity. Therefore, the development of efficient nonviral vectors allowing the induction of potent humoral and cell-mediated immunity is regarded as an imperative scientific challenge as well as a commercial breakthrough for the pharma industries. For a successful translation to the clinic, such nanocarriers should protect the antigens from mucosal enzymes, facilitate antigen uptake by microfold cells and allow the copresentation of robust, safe for human use, mucosal adjuvants to antigen-presenting cells. Finally, the developed formulations should exhibit accuracy regarding the administered dose, a major drawback of mucosal vaccines in comparison with parenteral ones.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
2
Concepts
Protein, Vaccination, Cell-mediated immunity, Antigen, Virus, Antibody, Humoral immunity, Immune system
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com